Bentley Pharmaceuticals Receives Approval to Market Selegiline Through Its European Subsidiary; Plans to Launch in the 4th Quarter.Business/Health Editors NORTH HAMPTON, N.H.--(BUSINESS WIRE)--Sept. 14, 2000 Bentley Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol) BNT Boston Naming Test (psychology) BNT Bermuda National Trust BNT Bulgarian National TV BNT Broadband Network Termination BNT Binary File Transfer ), a drug delivery company with a commercial presence in Europe, announced today that its wholly-owned subsidiary, Laboratorios Davur S.L., has been granted approval by the Spanish Ministry of Health to market selegiline in Spain as a generic. The product is planned for launch during the 4th quarter of 2000. The product is a CNS See Continuous net settlement. CNS See continuous net settlement (CNS). acting drug (commonly known as L-deprenyl) useful in the treatment of Parkinson's disease and is prescribed alone or in combination with levodopa levodopa: see l-dopa. levodopa or L-dopa Organic compound (L-3,4-dihydroxyphenylalanine) from which the body makes dopamine, a neurotransmitter deficient in persons with parkinsonism. . James R. Murphy, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented, "There are no generic versions of selegiline currently on the Spanish market. Therefore, we have an opportunity to obtain a significant market share over the next few years. According to the market data of IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. , the Spanish market for treating Parkinson's disease is approximately $39 million and is growing at an annual rate of 16%." Bentley Pharmaceuticals, Inc. is a drug delivery company focused upon improving the absorption of a wide range of drugs and peptides through proprietary drug delivery technologies which it intends to commercialize in the U.S. and other major markets by licensing to other pharmaceutical companies. Bentley also manufactures and commercializes branded and generic products in Europe for the treatment of cardiovascular, gastrointestinal, neurological and infectious diseases through its subsidiaries Laboratorios Belmac S.A. and Laboratorios Davur S.L. Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, the ability to find effective market distribution channels, development of new products, regulatory approval processes, the impact of competitive products or pricing, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Copies of the Company's press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion